The Editors of 麻豆官方Drug Information庐 (麻豆官方DI庐) wish to inform you of an error in the alpelisib monograph 10:00.
In the 麻豆官方monograph, the error appears under the subhead Breast Cancer, in Dosage and Administration: Dosage.聽 (This is in the second column on page 870 of the printed edition of 麻豆官方DI 2022庐.) In the first sentence under this subhead, the statement should read:
鈥淔or use in combination with fulvestrant in the treatment of hormone receptor-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer in men and postmenopausal women with disease progression following endocrine therapy, the recommended adult dosage of alpelisib is 300 mg (two 150-mg tablets) once 诲补颈濒测.鈥�
In the 麻豆官方Essentials monograph, this statement should read:
鈥淥ral: 300 mg (two 150-mg tablets) once daily; use in combination with fulvestrant 500 mg by IM injection on days 1, 15, and 29 and then once monthly thereafter.鈥�